Patents by Inventor Maxim Egorov

Maxim Egorov has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230181604
    Abstract: Mitochondrially targeted antioxidants are used to prevent and treat severe inflammatory conditions including viral infection (such as COVID-19), systemic shock, trauma, burns, surgery associated with significant tissue damage, toxic damage, and damage associated with autoimmune reactions.
    Type: Application
    Filed: April 5, 2021
    Publication date: June 15, 2023
    Inventors: Maxim V. SKULACHEV, Roman ZINOVKIN, Alexander ANDREEV-ANDRIEVSKY, Maxim EGOROV, Elena KARGER, Anton PETROV, Lawrence FRIEDHOFF
  • Patent number: 10238671
    Abstract: The invention relates to hydrosoluble hydroxybisphosphonic derivatives of doxorubicin of formula (I) and the pharmaceutically acceptable salts thereof. The invention also relates to the use of said compounds as a drug, especially in the treatment of a bone tumour. The invention further relates to the pharmaceutical compositions comprising such compounds, the methods for the synthesis thereof and synthesis intermediates.
    Type: Grant
    Filed: November 20, 2015
    Date of Patent: March 26, 2019
    Assignee: Atlanthera
    Inventors: Maxim Egorov, Jean-Yves Goujon, Ronan Le Bot, Emmanuelle David
  • Publication number: 20170319606
    Abstract: The invention relates to hydrosoluble hydroxybisphosphonic derivatives of doxorubicin of formula (I) and the pharmaceutically acceptable salts thereof. The invention also relates to the use of said compounds as a drug, especially in the treatment of a bone tumour. The invention further relates to the pharmaceutical compositions comprising such compounds, the methods for the synthesis thereof and synthesis intermediates.
    Type: Application
    Filed: November 20, 2015
    Publication date: November 9, 2017
    Applicant: Atlanthera
    Inventors: Maxim Egorov, Jean-Yves Goujon, Ronan Le Bot, Emmanuelle David
  • Patent number: 9546159
    Abstract: The present invention relates to a compound of formula (I) in which: -m is an integer from 0 to 3, preferably from 0 to 2; n is an integer from 0 to 3, preferably from 0 to 2; m+n?1; EAG is an electro-attractive group chosen independently from among a halogen atom, an NO2, CF3, CCI3, CN, CO2H, (C?O)NR2, CH?NR, (C?S)OR, (C?O)SR, CS2R, SO2R, SO2NR2, SO3R, P(O)(OR)2, P(O)(R)2, B(OR)2 group where R is a (C1-C6) alkyl radical, a phenyl group or a hydrogen atom; A is a saturated or unsaturated, linear or branched hydrocarbon chain including 1 to 10 atoms of carbon; and R1 and R2 each represent independently from one another a hydrogen atom, a CO-(Ci-C6)-alkyl, (C1-C6) alkyl, phenyl or phenyl-(C1-C6)-alkyl group, in which R1 and R2 form, together with the nitrogen atom they carry, a 5- to 15-member heterocycle, optionally substituted by a (C1-C6) alkyl group; including its stereoisomers and the mixtures thereof, or a pharmaceutically acceptable salt of same.
    Type: Grant
    Filed: October 14, 2013
    Date of Patent: January 17, 2017
    Assignee: Centre National de la Recherche Scientifique (CNRS)
    Inventors: Pascal Collin, Maxim Egorov, Bernard Delpech, Joanna Bakala, Maria Achab, Jérome Bignon, Odile Thoison, Michel Benechie
  • Publication number: 20150344460
    Abstract: The present invention relates to a compound of formula (I) in which: —m is an integer from 0 to 3, preferably from 0 to 2; n is an integer from 0 to 3, preferably from 0 to 2; m+n?1; EAG is an electro-attractive group chosen independently from among a halogen atom, an NO2, CF3, CCI3, CN, CO2H, (C?O)NR2, CH?NR, (C?S)OR, (C?O)SR, CS2R, SO2R, SO2NR2, SO3R, P(O)(OR)2, P(O)(R)2, B(OR)2 group where R is a (C1-C6) alkyl radical, a phenyl group or a hydrogen atom; A is a saturated or unsaturated, linear or branched hydrocarbon chain including 1 to 10 atoms of carbon; and R1 and R2 each represent independently from one another a hydrogen atom, a CO-(Ci-C6)-alkyl, (C1-C6) alkyl, phenyl or phenyl-(C1-C6)-alkyl group, in which R1 and R2 form, together with the nitrogen atom they carry, a 5- to 15-member heterocycle, optionally substituted by a (C1-C6) alkyl group; including its stereoisomers and the mixtures thereof, or a pharmaceutically acceptable salt of same.
    Type: Application
    Filed: October 14, 2013
    Publication date: December 3, 2015
    Inventors: Pascal Collin, Maxim Egorov, Bernard Delpech, Joanna Bakala, Maria Achab, Jérome Bignon, Odile Thoison, Michel Benechie
  • Patent number: 9173946
    Abstract: The present invention relates to a bifunctional hydroxy-bisphosphonic acid derivative of formula (I) below: or a pharmaceutically-acceptable salt thereof, a method for producing the same, pharmaceutical compositions containing the same, and the use thereof as a medicament, as well as a compound of formula (II) below: or a pharmaceutically-acceptable salt thereof, and the use thereof for producing a vectorized molecule of therapeutic or diagnostic purpose.
    Type: Grant
    Filed: March 28, 2012
    Date of Patent: November 3, 2015
    Assignee: ATLANTHERA
    Inventors: Maxim Egorov, Jean-Yves Goujon, Ronan Le Bot
  • Publication number: 20140086843
    Abstract: The present invention relates to a bifunctional hydroxy-bisphosphonic acid derivative of formula (I) below: or a pharmaceutically-acceptable salt thereof, a method for producing the same, pharmaceutical compositions containing the same, and the use thereof as a medicament, as well as a compound of formula (II) below: or a pharmaceutically-acceptable salt thereof, and the use thereof for producing a vectorized molecule of therapeutic or diagnostic purpose.
    Type: Application
    Filed: March 28, 2012
    Publication date: March 27, 2014
    Applicant: ATLANTHERA
    Inventors: Maxim Egorov, Jean-Yves Goujon, Ronan Le Bot
  • Patent number: 8361993
    Abstract: The present invention relates to hydroxy-bisphosphonic acid derivatives corresponding to general formula (I): in which: -n and m denote, independently of one another, an integer ranging from 1 to 4, —X denotes an oxygen atom or an N—R3 group, —R1 and R3 denote, independently of one another, a linear or branched C1 to C6 alkyl group, and —R2 denotes a residue of a molecule of therapeutic or diagnostic interest, or pharmaceutically acceptable salts of said derivatives, and also the method for the preparation thereof and the therapeutic or diagnostic use thereof.
    Type: Grant
    Filed: January 5, 2009
    Date of Patent: January 29, 2013
    Assignees: Universite de Nantes, Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique (CNRS)
    Inventors: Maxim Egorov, Yannick Fortun, Dominique Heymann, Jacques Lebreton, Monique Mathe, Marc Padrines, Francoise Redini
  • Publication number: 20100311695
    Abstract: The present invention relates to hydroxy-bisphosphonic acid derivatives corresponding to general formula (I): in which: -n and m denote, independently of one another, an integer ranging from 1 to 4, —X denotes an oxygen atom or an N—R3 group, —R1 and R3 denote, independently of one another, a linear or branched C1 to C6 alkyl group, and —R2 denotes a residue of a molecule of therapeutic or diagnostic interest, or pharmaceutically acceptable salts of said derivatives, and also the method for the preparation thereof and the therapeutic or diagnostic use thereof.
    Type: Application
    Filed: January 5, 2009
    Publication date: December 9, 2010
    Inventors: Maxim Egorov, Yannick Fortun, Dominique Heymann, Jacques Lebreton, Monique Mathe, Marc Padrines, Francoise Redini